Now, more than ever, innovation in the pharmaceutical industry is the product of successful collaboration. Partnerships are critical to our strategy. Working together with other companies, medical institutions and scientific organizations from the public and private sectors, we will not only realize our goals to find new medicines but also grow our company. Recent partnerships include:
- Partnership with Viiv for Tivicay® (dolutegravir) approved in August 2013. This medication is an important option in the treatment of HIV.
- Partnership with Egalet for the development and commercialization of multiple oral abuse-deterrent hydrocodone opioid products using Egalet’s proprietary abuse-deterrent technology.
TIVICAY is a registered trademark of the ViiV Healthcare group of companies.